Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Human Metabolome Technologies Days Payable?
Human Metabolome TechnologiesTSE:6090 +3.37%62 Days Payable is 15.03 as of Mar. 2026, which is 487% above its 10-year median of 2.56. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円693.69 (Fairly Valued). The stock has 3 warning signs investors should review. Among 189 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks worse than 94.71% on this metric.
The historical rank and industry rank for Human Metabolome Technologies's Days Payable or its related term are showing as below:
TSE:6090'
s Days Payable Range Over the Past 10 Years
Min: 0.01 Med: 2.56 Max: 11.53
Current: 10.67
During the past 13 years, Human Metabolome Technologies's highest Days Payable was 11.53. The lowest was 0.01. And the median was 2.56.
TSE:6090's Days Payable is ranked worse than 94.71% of 189
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.09
vs TSE:6090: 10.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6090 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Days Payable falls into.
Human Metabolome Technologies Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Days Payable of 15.03 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Human Metabolome Technologies and its competitors. This is 487% above median its historical median of 2.56. Over the past decade, Human Metabolome Technologies' Days Payable has ranged from 0.01 to 11.53. According to the industry distribution chart, Human Metabolome Technologies ranks #179 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 94.7%.
Is Human Metabolome Technologies' Days Payable too high?
Human Metabolome Technologies' current Days Payable of 15.03 is 487% above median its 10-year median of 2.56. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 11.53. The Medical Diagnostics & Research industry median Days Payable is 65.09. Human Metabolome Technologies' value of 15.03 is 76.9% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #179 out of 189 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #179 out of 189 companies for Days Payable. This places Human Metabolome Technologies in the lower half of its industry. The industry median Days Payable is 65.09. Human Metabolome Technologies' value of 15.03 is 76.9% below this benchmark. Historically, Human Metabolome Technologies' own Days Payable has ranged from 0.01 to 11.53 over the past decade. While the company's 10-year median is 2.56 vs. the industry median of 65.09, Human Metabolome Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.09, based on 189 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Days Payable of 15.03 is 76.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Days Payable is 15.03, which is 487% above median its own 10-year median of 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Fairly Valued. The stock's GF Value™ is 円693.69, compared to a current price of 円645.00 — trading 7% below its estimated fair value. The current Days Payable is 15.03, which is 487% above median its 10-year median of 2.56 and 76.9% below the Medical Diagnostics & Research industry median of 65.09. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Days Payable is 15.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円645.00 is trading 7% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Fairly Valued.
Key valuation signals for TSE:6090:
Days Payable: 15.03 (487% above median its 10-year median of 2.56)
GF Value™: 円693.69 vs. price of 円645.00 (7% below fair value)
Industry Position: 76.9% below the Medical Diagnostics & Research median (#179 of 189)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
